Celularity Inc Financial Summary

Quick Answer

Celularity Inc reported Total Revenue of $54.22 million for fiscal year 2024.

Celularity Inc — Key Financials by Year

Metric 2024 2023 2022 2021 2020 2019
Total Revenue $54.22M
+138.1%
$22.77M
+26.7%
$17.98M
-15.7%
$21.34M
+49.4%
$14.28M
Revenue (ASC 606) $54.22M
+138.1%
$22.77M
+26.7%
$17.98M
-15.7%
$21.34M
+49.4%
$14.28M
Net Income -$57.89M
+70.5%
-$196.29M
-1483.1%
$14.19M
+114.2%
-$100.12M
+51.9%
-$208.23M
-8386.3%
$2.51M
Diluted EPS -$2.64
+76.0%
-$11.02
-1260.0%
$0.95
+163.8%
-$1.49
Total Assets $132.68M
-7.8%
$143.89M
-64.1%
$401.07M
-3.2%
$414.13M
-3.9%
$431.01M
+47.8%
$291.61M
+167050.3%
Cash and Equivalents $738.0K
+225.1%
$227.0K
-98.4%
$13.97M
-62.5%
$37.24M
-31.4%
$54.31M
+5822.6%
$917.0K
+3611.5%
Stockholders Equity $8.84M
-78.4%
$40.96M
-79.4%
$198.90M
+100.1%
$99.42M
+118.7%
-$531.40M
-62.3%
-$327.42M
-1369943.5%
R&D Expense $17.39M
-42.9%
$30.46M
-61.1%
$78.36M
-11.3%
$88.35M
+67.6%
$52.71M
Operating Income -$38.36M
+80.1%
-$192.29M
-651.1%
-$25.60M
+76.5%
-$109.06M
+28.2%
-$151.93M
-26820.9%
-$564.3K
Shares Outstanding 22.55M
+16.4%
19.38M
+30.1%
14.89M
-88.0%
124.31M
+570.9%
18.53M

Most Recent Quarter

Metric Quarter Ending Value YoY QoQ
Total Revenue September 30, 2025 $5.28M -43.2% -7.9%
Revenue (ASC 606) September 30, 2025 $5.28M -43.2% -7.9%
Net Income September 30, 2025 -$23.08M -43.3% +5.9%
Diluted EPS September 30, 2025 -$0.88 -20.5% +13.7%
Total Assets September 30, 2025 $114.24M -11.3% -5.0%
Cash and Equivalents September 30, 2025 $120.0K -9.8% -86.1%
Long-Term Debt June 30, 2023 $17.03M +258.8%
Stockholders Equity September 30, 2025 -$20.09M -216.3% +21.2%
R&D Expense September 30, 2025 $4.60M +17.4% +37.2%
Operating Income September 30, 2025 -$12.90M -11.9% +18.7%
Shares Outstanding September 30, 2025 28.22M +28.3% +14.7%
  • Celularity Inc reported Total Revenue of $54.22 million for fiscal year 2024.
  • Celularity Inc showed an increase of +138.1% in Total Revenue compared to the prior fiscal year.
  • Celularity Inc reported Revenue (ASC 606) of $54.22 million for fiscal year 2024.
  • Celularity Inc showed an increase of +138.1% in Revenue (ASC 606) compared to the prior fiscal year.
  • Celularity Inc reported Net Income of -$57.89 million for fiscal year 2024.
  • Celularity Inc showed an increase of +70.5% in Net Income compared to the prior fiscal year.
  • Celularity Inc reported Diluted EPS of $2.64 per share (loss) for fiscal year 2024.
  • Celularity Inc showed an increase of +76.0% in Diluted EPS compared to the prior fiscal year.
  • Celularity Inc reported Total Assets of $132.68 million for fiscal year 2024.
  • Celularity Inc showed a decrease of -7.8% in Total Assets compared to the prior fiscal year.
  • Celularity Inc reported Cash and Equivalents of $738.0 thousand for fiscal year 2024.
  • Celularity Inc showed an increase of +225.1% in Cash and Equivalents compared to the prior fiscal year.
  • Celularity Inc reported Stockholders Equity of $8.84 million for fiscal year 2024.
  • Celularity Inc showed a decrease of -78.4% in Stockholders Equity compared to the prior fiscal year.
  • Celularity Inc reported R&D Expense of $17.39 million for fiscal year 2024.
  • Celularity Inc showed a decrease of -42.9% in R&D Expense compared to the prior fiscal year.
  • Celularity Inc reported Operating Income of -$38.36 million for fiscal year 2024.
  • Celularity Inc showed an increase of +80.1% in Operating Income compared to the prior fiscal year.
  • Celularity Inc reported Shares Outstanding of 22.55 million shares for fiscal year 2024.
  • Celularity Inc showed an increase of +16.4% in Shares Outstanding compared to the prior fiscal year.
  • All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.

Last verified:

Leave a Comment